Oncotarget

View Archive »

About The Cover

PKM2 contributes to metabolic reprogramming and cancer progression by serving as a PHD3-dependent coactivator for HIF-1. Prolyl hydroxylation of PKM2 by PHD3 promotes the interaction of PKM2 with HIF-1α, thereby stabilizing HIF-1 binding to the HRE of target genes, recruitment of coactivator p300, histone acetylation, and subsequent transcription of HIF-1 target genes, which encode proteins that are involved in metabolic reprogramming, angiogenesis, and many other critical aspects of cancer progression. See Luo and Semenza.

Table of Contents

Editorial

Allogeneic adoptive cell transfer therapy as a potent universal treatment for cancer

https://doi.org/10.18632/oncotarget.300

Assaf Marcus, and Zelig Eshhar
525-526
Abstract  |  PDF  |  Full Text  |  How to cite

Editorial Comments

Paracrystals of STAT proteins and their dissolution by SUMO: How reduced transcription factor solubility increases cytokine signaling

https://doi.org/10.18632/oncotarget.307

Mathias Droescher, Andreas Begitt, and Uwe Vinkemeier
527-528
Abstract  |  PDF  |  Full Text  |  How to cite

Research Papers

A breast cancer metaanalysis of two expression measures of chromosomal instability reveals a relationship with younger age at diagnosis and high risk histopathological variables

https://doi.org/10.18632/oncotarget.298

David Endesfelder, Nicholas McGranahan, Nicolai Juul Birkbak, Zoltan Szallasi, Maik Kschischo, Trevor Graham, and Charles Swanton
529-537
Abstract  |  PDF  |  Full Text  |  How to cite

Involvement of Akt1 and mTOR in Sensitivity of Breast Cancer to Targeted Therapy

https://doi.org/10.18632/oncotarget.302

Melissa L. Sokolosky, Kristin M. Stadelman, William H. Chappell, Stephen L. Abrams, Alberto M. Martelli, Franca Stivala, Massimo Libra, Ferdinando Nicoletti, Lyudmyla B. Drobot, Richard A. Franklin, Linda S. Steelman, and James A. McCubrey
538-550
Abstract  |  PDF  |  Full Text  |  How to cite

Research Perspectives

Pyruvate kinase M2 regulates glucose metabolism by functioning as a coactivator for hypoxiainducible factor 1 in cancer cells

https://doi.org/10.18632/oncotarget.299

Weibo Luo, and Gregg L. Semenza
551-556
Abstract  |  PDF  |  Full Text  |  How to cite

Targeting cancer with peptide aptamers

https://doi.org/10.18632/oncotarget.297

Renaud Seigneuric, Jessica Gobbo, Pierre Colas, and Carmen Garrido
557-561
Abstract  |  PDF  |  Full Text  |  How to cite

Targeting invadopodia to block breast cancer metastasis

https://doi.org/10.18632/oncotarget.301

Mark A Eckert, and Jing Yang
562-568
Abstract  |  PDF  |  Full Text  |  How to cite

Wnt and Kras signalingdark siblings in lung cancer

https://doi.org/10.18632/oncotarget.305

Eugenia C. Pacheco-Pinedo, and Edward E. Morrisey
569-574
Abstract  |  PDF  |  Full Text  |  How to cite

Evi1 forms a bridge between the epigenetic machinery and signaling pathways

https://doi.org/10.18632/oncotarget.304

Akihide Yoshimi, and Mineo Kurokawa
575-586
Abstract  |  PDF  |  Full Text  |  How to cite


Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLC
By using our site you are giving us permission to use cookies. This website collects cookies to deliver a better user experience, and to analyze our website traffic and performance. Personal data is not collected.